Free fatty acids and insulin resistance

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 2, 2007, Pages 142-148

  Delarue, Jacques ^a,c   Magnan, Christophe ^b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Acyl CoA; Ceramide; Peroxisome proliferator activated receptor; Serine threonine kinase

Indexed keywords

ACYL COENZYME A; CERAMIDE; DIACYLGLYCEROL; FATTY ACID; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN SERINE KINASE; SALICYLIC ACID DERIVATIVE; TRIACYLGLYCEROL;

ADIPOSE TISSUE; DIABETES MELLITUS; ENZYME ACTIVATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOLYSIS; LIVER; METABOLIC DISORDER; METABOLITE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADIPOSE TISSUE; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE; LIPOLYSIS; LIVER; MUSCLE, SKELETAL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 33846854374     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e328042ba90     Document Type: Review

References (50)

1. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70:1560-1566. A good review for lecturers who are especially interested in the consequences of lipotoxicity for the kidney.
2. Kusunoki J, Kanatani A, Moller DE. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome. Endocrine 2006; 29:91-100. An interesting review of targets for modulation of fatty acid metabolism from the perspective of drug development.
3. Langin D. Control of fatty acid and glycerol release in adipose tissue lipolysis. C R Biol 2006; 329:598-607. An up-to-date review about regulation of lipolysis.
4. Cahill GF. Fuel metabolism in starvation. Annu Rev Nutr 2006; 26:1-22. An excellent review about the adaptation of fuel metabolism during starvation by one of the more concerned researchers in this field.
5. Horowitz JF. Fatty acid mobilization from adipose tissue during exercise. Trends Endocrinol Metab 2003; 14:386-392.
6. Blaak EE. Metabolic fluxes in skeletal muscle in relation to obesity and insulin resistance. Best Pract Res Clin Endocrinol Metab 2005; 19:391-403.
7. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl 2004; 143:9-21.
8. Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 2005; 19:625-635.
9. Koutsari C, Jensen MD. Thematic review series: patient-oriented research. Free fatty acid metabolism in human obesity. J Lipid Res 2006; 47:1643-1645. A very detailed review describing the major works of Jensen et al. about FFA matabolism in regard to body-fat distribution in normal, obese and type 2 diabetic subjects.
10. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697-738.
11. Jensen MD, Johnson CM. Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women. Metabolism 1996; 45:662-666.
12. Martin ML, Jensen MD. Effects of body fat distribution on regional lipolysis in obesity. J Clin Invest 1991; 88:609-613.
13. Nielsen S, Guo Z, Johnson CM, et al. Splanchnic lipolysis in human obesity. J Clin Invest 2004; 113:1582-1588.
14. Basu A, Basu R, Shah P, et al. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2001; 280:E1000-E1006.
15. Nguyen TT, Mijares AH, Johnson CM, Jensen MD. Postprandial leg and splanchnic fatty acid metabolism in nonobese men and women. Am J Physiol Endocrinol Metab 1996; 271:E965-E972.
16. Guo Z, Hensrud DD, Johnson CM, Jensen MD. Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 1999; 48:1586-1592.
17. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1:785-789.
18. Wolfe RR. Metabolic interactions between glucose and fatty acids in humans. Am J Clin Nutr 1998; 67 (3 suppl):519S-526S.
19. Roden M. How free fatty acids inhibit glucose utilization in human skeletal muscle. News Physiol Sci 2004; 19:92-96.
20. Shulman GI. Unraveling the cellular mechanism of insulin resistance in humans: new insights from magnetic resonance spectroscopy. Physiology (Bethesda) 2004; 19:183-190.
21. Perseghin G, Scifo P, De Cobelli F, et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999; 48:1600-1606.
22. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr 2002; 22:325-346.
23. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol Endocrinol Metab 1999; 277:E1130-E1141.
24. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE. Markers of capacity to utilize fatty acids in human skeletal muscle: relation to insulin resistance and obesity and effects of weight loss. FASEB J 1999; 13:2051-2060.
25. Roden M. Muscle triglycerides and mitochondrial function: possible mechanisms for the development of type 2 diabetes. Int J Obes (Lond) 2005; 29 suppl 2:S111-S115.
26. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119 (5 Suppl 1):S10-S16. An excellent review on the basic mechanisms of insulin resistance.
27. Schinner S, Scherbaum WA, Bornstein SR, Barthel A. Molecular mechanisms of insulin resistance. Diabet Med 2005; 22:674-682.
28. Kim JK, Fillmore JJ, Sunshine MJ, et al. PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 2004; 114:823-827.
29. Savage DB, Petersen KF, Shulman GI. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45:828-833.
30. Schernthaner GH, Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand J Clin Lab Invest Suppl 2005; 240:30-40.
31. Vettor R, Milan G, Rossato M, Federspil G. Review article: adipocytokines and insulin resistance. Aliment Pharmacol Ther 2005; 22 suppl 2:3-10.
32. Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002; 5:545-549.
33. Yki-Jarvinen H. Fat in the liver and insulin resistance. Ann Med 2005; 37:347-356.
34. Clore JN, Glickman PS, Nestler JE, Blackard WG. In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans. Am J Physiol Endocrinol Metab 1991; 261:E425-E429.
35. Chen X, Iqbal N, Boden G. The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 1999; 103:365-372.
36. Lam TK, Carpentier A, Lewis GF, et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003; 284:E863-E873.
37. Boden G, Chen X, Capulong E, Mozzoli M. Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 2001; 50:810-816.
38. Boden G, Cheung P, Stein TP, et al. FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis. Am J Physiol Endocrinol Metab 2002; 283:E12-E19.
39. Kim JK, Gavrilova O, Chen Y, et al. Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 2000; 275:8456-8460.
40. Olefsky JM, Saltiel AR. PPARgamma and the treatment of insulin resistance. Trends Endocrinol Metab 2000; 11:362-367.
41. Nguyen MT, Satoh H, Favelyukis S, et al. JNK and tumor necrosis factor-{alpha} mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005; 280:35361-35371.
42. Engeli S, Bohnke J, Feldpausch M, et al. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004; 12:9-17.
43. Kannisto K, Pietilainen KH, Ehrenborg E, et al. Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 2004; 89:4414-4421.
44. Beltowski J. Adiponectin and resistin-new hormones of white adipose tissue. Med Sci Monit 2003; 9:RA55-RA61.
45. Alzahrani AS. Resistin: can we resist its role in insulin resistance? Ann Saudi Med 2005; 25:281-282.
46. Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol 2004; 82:170-190.
47. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89:200-206.
48. Schneider JG, von Eynatten M, Schiekofer S, et al. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005; 28:2181-2186.
49. Borst SE, Conover CF, Bagby GJ. Association of resistin with visceral fat and muscle insulin resistance. Cytokine 2005; 32:39-44.
50. Leroyer SN, Tordjman J, Chauvet G, et al. Rosiglitazone controls fatty acid cycling in human adipose tissue by means of glyceroneogenesis and glycerol phosphorylation. J Biol Chem 2006; 281:13141-13149. A very new work on the role of modulation of glyceroneogenesis by rosiglitazone which demonstrates an alternative mechanism for the effects of rosiglitazone on insulin sensitivity and FFA metabolism.